4 Spam-Free Article(s) Found
||Eli Lilly and Company
Oct 17, 2019 - Lilly's (LLY) immunotherapy candidate, pegilodecakin, falls short of meeting the primary endpoint of OS benefit in a phase III study investigating its usage in metastatic pancreatic cancer.
Oct 17, 2019 - Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance are likely to have performed well. Let's see if these along with its older products lead to an earnings beat for the company in Q3.
Oct 16, 2019 - Lilly (LLY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.